PRO-spectus blog

Oncology Launch Reaches a 100% Approval Rate | PRO-spectus

PRO Spectus — Thu, 29 Oct 2026 14:54:26 GMT

SCENARIO AND SERVICE

A manufacturer of a new oncology therapy launched a high-cost therapy where every case required significant reimbursement and clinical expertise. Individual cases were complex, so success depended on coordination across several teams.

PRO’s case management teams submitted each case thoroughly and accurately, and pursued independent medical review on every denial. The team kept the treating facility, the case management team, and the payor continuously aligned, backed by clinical navigation and affordability support for patients.

GRAPHIC

CONCLUSION

For CY 2026 to date, the program has achieved a 100% approval rate, with enrollment volume up 107% year over year. All CMS PPS-exempt cancer hospitals are participating in the program, alongside commercial facilities. When every case is submitted thoroughly and every denial receives independent medical review, complex oncology therapies can reach patients with confidence. Learn more about our Patient Support and Hub Services.

SEO and AIO Elements

• Page title: Oncology Launch Case Management: 100% Approval Rate | PRO-spectus

• Meta description: See how PRO-spectus case management, independent medical review, and cross-functional coordination supported a 100% approval rate in a high-cost oncology launch.

• Graphic alt text: Three result panels for an oncology launch: 100% approval rate for CY 2026 to date, 107% increase in enrollment volume year over year, and all CMS PPS-exempt cancer hospitals participating in the program.

• Keywords to add once the product is confirmed: oncology therapy launch, oncology case management, independent medical review, denial appeal, high-cost therapy access, CMS PPS-exempt cancer hospitals, clinical navigation, affordability support.

Zero Coverage Launch Reaches 95% of Lives | PRO-spectus

PRO Spectus — Thu, 29 Oct 2026 14:37:52 GMT

SCENARIO AND SERVICE

A manufacturer launched with no payor coverage policies in place, commercial or Medicaid. Without coverage, patients and providers had no clear path to treatment, and the company needed policies established quickly to keep its launch moving.

PRO launched a patient support program (PSP) that included an experienced payor case management team. The team engaged payors and state Medicaid programs persistently, with outreach shaped by each payor's specific considerations. Coverage came through inclusion in medical policy and, for some payors, through contracted specialty pharmacy networks.

CONCLUSION

Within four years of launch, 95% of commercial lives had received authorization and 84% of Medicaid states, 42 in total, were granting authorization. Persistent, payor-specific engagement helped turn a zero coverage launch into broad access for patients. Learn more about our Market Access and Patient Support services.

Virtual FRMs Cut Open A/R 42% in Buy and Bill | PRO-spectus

PRO Spectus — Thu, 29 Oct 2026 14:24:21 GMT

SCENARIO AND SERVICE

A manufacturer distributing through the buy-and-bill channel saw J-code reimbursement outcomes in hospital outpatient department (HOPD) and ambulatory surgery center (ASC) settings that were affecting sales and leaving cases with open accounts receivable (A/R).

PRO’s virtual field reimbursement managers (FRMs) provided reimbursement education to site-of-care staff. Each site learned about the coding, coverage, and payment requirements specific to its setting, so teams could better understand how claims for the product are processed.

GRAPHIC

CONCLUSION

Within two years of implementing the client support strategy, cases with open A/R fell 42%, while paid cases increased 429%. Clear, setting-specific reimbursement education helps sites of care understand each step of the J-code payment process. Learn more about our Revenue Cycle Management and virtual FRM services.

Virtual FRMs Speed a Drug Launch to Profit | PRO-spectus

PRO Spectus — Thu, 29 Oct 2026 14:21:25 GMT

SCENARIO AND SERVICE

A manufacturer was launching in phases across a range of care settings, including hospital outpatient departments, inpatient settings, ambulatory surgery centers (ASCs), and provider groups. Each setting has its own coding, coverage, and payment considerations.

PRO;s virtual field reimbursement managers (FRMs) provided reimbursement education and support tailored to each setting of care. Teams worked from the same launch plan and adjusted their approach by segment, so each type of site received information that fit the way it operates.

GRAPHIC

CONCLUSION

The client launched commercially in Q2 and reached profitability in Q4 of the same year, its first profitable commercial quarter, led largely by outpatient accounts. Growth continued into the following year, with net revenue more than tripling from Q3 to Q1. Tailored support for each setting of care helps a launch take hold across the full range of sites where patients are treated. Learn more about our Revenue Cycle Management and virtual FRM services.

Buy and Bill Volume Grows 254% | PRO-spectus

PRO Spectus — Thu, 29 Oct 2026 14:15:24 GMT

SCENARIO AND SERVICE

A manufacturer was building a buy and bill channel. For this model, coding, coverage, and payment all have to align before accounts can use a product with confidence, and unanswered questions in any one area can slow adoption.

PRO worked with stakeholders to connect the dots between coding, coverage, and payment. Our access teams educated accounts on purchasing and billing considerations, clarified coverage and payment requirements, and helped everyone stay aligned on approvals, coding, and next steps. Teams also gathered the claim barriers providers reported so the manufacturer could respond to them.

GRAPHIC

CONCLUSION

Buy and bill volume grew 190% in Year 3 and 254% in Year 4. When coding, coverage, and payment are clear, accounts can focus on getting patients to treatment. PRO-spectus access teams help keep everyone aligned from approval through payment. Learn more about our Market Access and Reimbursement services.

HOPD and ASC Access Drives 400% Volume Growth | PRO-spectus

PRO Spectus — Thu, 29 Oct 2026 13:58:01 GMT

SCENARIO AND SERVICE

A manufacturer was seeing usage prevalence in physician offices. To reach more patients, the product needed to be available in hospital outpatient departments (HOPDs) and ambulatory surgery centers (ASCs), where coding, coverage, and payment expectations are different.

PRO provided education to HOPD and ASC accounts on the coding, coverage, and payment expectations for their sites of care. Access teams helped stakeholders stay aligned on approvals and next steps, so new sites could begin using the product with a clear understanding of the process.

GRAPHIC

CONCLUSION

Total volume grew 400%, led by the entry of HOPDs and ASCs. Physician offices represented 90% of use in Year 1 and 47% by Year 4, while HOPDs reached 29% and ASCs 24%. Access teams that understand every site of care help a product reach patients wherever treatment is delivered. Learn more about our Market Access and Reimbursement services.

Clinical Navigators Triple Infusion Starts | PRO-spectus

PRO Spectus — Thu, 29 Oct 2026 13:48:43 GMT

SCENARIO AND SERVICE

A manufacturer wanted more patients to complete their first infusion and stay on treatment. Starting an infusion involves many steps, including patient engagement, logistics, and site readiness. A gap at any one of them can delay or end therapy.

PRO added a dedicated clinical navigator to the manufacturer's patient support program. Navigators provided education, reminders, and caregiver support from the first conversation. They coordinated with infusion sites on logistics from site readiness through the first infusion and ongoing visits and routed any clinical questions to the patient's care team.

Once the clinical navigators were in place, treatment starts more than tripled – growing from 20% of patients to over 70%. Adherence grew from 10% to a steady state of 86%.

Patients who know what to expect and feel supported are better prepared to begin and continue therapy. PRO’s clinical navigators can be paired with site-level coordination when a program calls for it.

Learn more about our Adherence & Engagement services.

Health Policy Made Easy: 10 Facts on Coverage | PRO-spectus

PRO Spectus — Thu, 29 Oct 2026 13:23:48 GMT

10 Facts to Make Health Policy Easy in a Complex World

Healthcare policy and the corresponding coverage for services in the United States are incredibly complex. Coverage varies between:

• Commercial
• Traditional CMS based coverage with Medicaid/Medicare
• Managed governmental plans
• Marketplace plans
• Self-funded versus fully funded

With nuances across employer groups, making sense of available coverage options has become increasingly challenging.

Policy Dictates Coverage

Health insurance companies play a significant role in determining the coverage of medical services. Five areas to know:

The process begins with the writing and application of medical policy criteria, which serve as guidelines for coverage decisions.
Each payor has its own medical coverage criteria, referred to as policies. These policies outline the conditions under which a service is considered medically necessary and therefore covered.
Insurers develop policies based on a variety of factors, including clinical evidence and cost-effectiveness.
Insurers review scientific literature, consult with medical experts, and consider input from patients and providers. Each payor has their own medical coverage criteria, referred to as policies.
These policies are not static. They are regularly updated to reflect advancements in medical technology, changes in clinical practice standards, and patterns of utilization.

Individual Medical Necessity Matters

While policy dictates what can be covered, individual patient circumstances significantly influence whether a service will be covered. This dynamic governs why the concept of ‘medical necessity’ ultimately comes into play. Five areas to know:

Medical necessity is the justification for a particular service, procedure, or treatment.
Necessity is determined based on the patient’s unique medical situation and the provider’s clinical judgment.
For a service to be deemed medically necessary, it must be considered reasonable, critical, and/or appropriate, based on evidence-based clinical standards of care. Maintaining a patient’s clinical documentation is crucial in this context. It provides the detailed medical information insurers need to determine whether a service meets their criteria for coverage.
This documentation, often provided by healthcare providers, includes diagnosis, prognosis, treatment plans, and patient progress notes.
While health policy sets the stage for what could be covered, an individual patient’s medical necessity often becomes the lead determinant of coverage. Understanding this interplay between policy and medical necessity can help patients and providers navigate the complex world of health coverage.

While the landscape appears complex, start your focus on policy and how it interacts with medical necessity.

Digital Therapeutics Coverage Guide | PRO-spectus

PRO Spectus — Thu, 29 Oct 2026 13:20:27 GMT

A practical guide for manufacturers preparing for payor review

Conventional wisdom says there is no real path to insurance coverage for digital therapeutics. That belief is understandable. Many DTx products enter the market without a familiar coding, coverage, and payment pathway, and many payors do not yet have policies designed for the category. Early cases are therefore evaluated individually and often begin with an experimental and investigational position.

Although this uncertainty can look like a dead end, it does not mean there is no path to coverage. It means your commercial and market access teams must build that path case by case. The barriers tend to repeat, and once your team understands where they come from, it can begin preparing for them long before your first payor review.

Why Coverage Feels Different

If your leadership team comes from technology, that background is a real asset. It brings product instincts and a builder's speed that healthcare companies often lack. The adjustment comes when your product enters the payor environment, where progress follows a different clock and a different set of rules.

FDA review gives your team a defined regulatory process. Coverage development does not offer the same predictable pathway. It proceeds case by case as payors evaluate the evidence presented for specific patients and covered populations.

This distinction matters because FDA and payors are answering different questions. FDA determines whether your product meets the regulatory standard for its pathway. Payors consider whether it is medically necessary, how its clinical value compares with available alternatives, and whether the evidence supports coverage for their members. Clearance or authorization is therefore an essential milestone, but it is the beginning of the coverage journey, not the end.

How your product is used also shapes that journey. Prescribers need a clear clinical use case, a workable workflow, and confidence that patients can access your product. If your digital therapeutic is episodic, with a defined beginning, middle, and end, it generally presents a clearer coverage story. Together, these considerations shape the access model your product will need. The earlier your commercial and market access teams plan for them, the sooner they can begin building a credible path to coverage.

The Experimental and Investigational Trap

Those differences often become visible when your first cases reach the payor. Your team may face an early wave of experimental and investigational denials with limited proven strategies for converting individual denials into approvals or approvals into broader policy change. Volume alone will not help if cases are worked inconsistently or stop at the first denial. A request for a medical policy will also rarely gain traction without a record of favorable case decisions and evidence of medical necessity.

When early cases are submitted without a fully developed strategy, denials can quickly become the pattern your team is forced to reverse. That is why the strategic work needs to happen before the first submission. Your team must identify the strongest initial cases, anticipate the issues each payor is likely to raise, assemble the clinical evidence and medical necessity rationale, and define the appeal pathway in advance. The objective is not simply to overturn one denial. It is to establish favorable outcomes that can become the foundation for the cases that follow.

The Costly Shortcut of Bypassing the Payor

An early wave of denials can make a cash pay or patient assistance option feel like the fastest solution. It can solve immediate access, but if coverage is never requested, the payor sees neither the demand nor the evidence behind those cases. The goal is not to delay patient support. Your access model should pair timely access with a deliberate coverage process by submitting eligible cases, appealing supported denials, and capturing outcomes your team can use in future reviews.

What This Looks Like for Your Team

Building coverage starts before the first case is submitted. Your initial cases establish the record that later cases will either reinforce or have to overcome. Your team should therefore select and prepare them with likely payor objections in mind, support each case with complete clinical documentation, and map the review and appeal path before submission.

A favorable outcome helps the patient in front of you and gives your team a model for the cases that follow. Your team should capture the evidence presented, the medical necessity rationale, the payor issue addressed, and what ultimately moved the decision. Applying those insights consistently allows later cases to strengthen the emerging coverage story.

Over time, those outcomes create a body of evidence specific to each payor. Your team can use that evidence to strengthen future submissions, address recurring objections, and support a broader policy conversation. Bridge or assistance programs can maintain timely patient access while the coverage strategy develops.

You should expect this work to take time, persistence, and specialized expertise. Coverage decisions are built on evidence, and your evidence base grows one patient, one appeal, and one payor decision at a time. If your team commits to the process, you can replace a stack of disconnected denials with a credible and increasingly repeatable coverage story.

A Coverage Model Built for the Category

Your coverage strategy cannot simply copy a familiar pharmaceutical commercialization model. It must reflect how digital therapeutics are evaluated, prescribed, accessed, and reimbursed.

Coverage will not emerge from a single meeting, policy request, or successful appeal. Your evidence base grows as your team works cases consistently, learns from payor objections, and applies those insights to the next submission.

Your path to coverage may not be paved, but it can be built one case, one appeal, one precedent, and one payor policy at a time.

Does AI Have a Place in Health Insurance? | PRO-spectus

PRO Spectus — Thu, 29 Oct 2026 13:14:37 GMT

Does AI have a place in Health Insurance? What we know today.

The integration of artificial intelligence (AI) is revolutionizing the health insurance industry. AI promises to enhance efficiency, accuracy, and cost-effectiveness, but also raises considerations regarding data privacy, bias, and consumer transparency. The Centers for Medicare & Medicaid Services (CMS) has provided guidance on the responsible use of AI, emphasizing the importance of maintaining compliance with regulatory requirements and individualized patient care.

How AI May Help:

Speed and Efficiency: AI can significantly reduce the time required for prior authorization and claim payment decisions. Automated systems can intake and process requests in real-time, leading to faster approvals and payments.
Consistency and Accuracy: AI algorithms can ensure the consistent application of guidelines and policies, reducing human error.
Cost Savings: By automating routine tasks, AI can lower administrative costs. This can result in optimized savings for both insurers and policyholders.
Fraud Detection: AI can analyze large data sets to identify patterns indicative of fraudulent claims, which support fraud prevention and mitigate financial losses.
Elevated Customer Experience: More expedient and accurate decisions enhance customer satisfaction. Policyholders and providers each benefit from fewer delays in the claims resolution process.

How AI May Hinder:

Data Privacy Concerns: The use of AI necessitates managing sensitive personal health information. Establishing comprehensive data privacy and security safeguards is paramount when adopting an AI solution.
Bias and Errors in Decision-Making: AI systems can inadvertently perpetuate biases or engage in erroneous decisions subject to the data underpinning their learning models. This could lead to suboptimal outcomes, potential discrimination, and delay of medically necessary care.
High Implementation Costs: Developing and implementing AI systems requires significant upfront investment outlay in technology and training. Smaller companies with more judicious budgets may find challenges in deploying the these cost to implement AI.
Lack of Transparency: AI decision-making processes can be complex and opaque. This lack of transparency can make it difficult for policyholders to understand the reasoning behind certain decisions.
Dependence on Technology: Over-reliance on AI systems can make companies vulnerable to technical failures and cyberattacks. Ensuring robust cybersecurity measures is critical.

Pull Quote

There is immense potential in the use of artificial intelligence in healthcare. However, regulatory agencies and companies alike must ensure that patient access to care is not compromised, and a transparent process is established.